Hospital
De Craig Ranch, LLC
De Craig Ranch, LLC was paid $13.97M by Medicaid between Jan 2018 and Dec 2024, across 127 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoDE CRAIG RANCH, LLC
NORTH LAS VEGAS, NV 89032
NORTH LAS VEGAS, NV 89032
33aNPI1578007514assigned 12/09/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.97M
24GClaims671,258
24DCodes billed127
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#15 of 36
Median peer was paid$7.64M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BUCK, JOHN controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,163 | $389K | |
| 2019 | 94,348 | $1.77M | |
| 2020 | 98,938 | $1.99M | |
| 2021 | 117,570 | $2.63M | |
| 2022 | 112,540 | $2.61M | |
| 2023 | 115,594 | $2.53M | |
| 2024incomplete | 99,105 | $2.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 32,243 | 28,425 | $2.55M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 51,752 | 46,130 | $2.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 19,097 | 17,099 | $2.18M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 8.0% | 4,607 | 4,216 | $1.12M |
| 87428 | 4.2% | 15,528 | 14,447 | $593K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 3,874 | 3,545 | $354K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 2,337 | 2,153 | $350K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 15,713 | 13,769 | $336K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 4,839 | 4,550 | $287K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 7,737 | 7,349 | $269K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.6% | 837 | 766 | $223K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 12,768 | 10,872 | $213K |
115 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,805 | $121K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,609 | $119K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,190 | $115K |
| 76801 | <1% | 1,552 | $112K | |
| 71045 | Radiologic examination, chest; single view | <1% | 11,893 | $111K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,520 | $106K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,194 | $89K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,970 | $88K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,310 | $86K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,785 | $69K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,788 | $68K |
| 81025 | <1% | 19,847 | $66K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 637 | $66K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,577 | $65K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,584 | $63K |
| 80051 | <1% | 18,818 | $63K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,257 | $60K |
| 80053 | Comprehensive metabolic panel | <1% | 12,252 | $60K |
| 82550 | <1% | 19,024 | $60K | |
| G0378 | Hospital observation service, per hour | <1% | 570 | $58K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,317 | $50K |
| 84484 | <1% | 10,948 | $50K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,886 | $50K |
| 82977 | <1% | 14,326 | $49K | |
| 76830 | Ultrasound, transvaginal | <1% | 514 | $47K |
| 83880 | <1% | 3,137 | $46K | |
| 82565 | <1% | 18,821 | $46K | |
| 82150 | <1% | 14,522 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 656 | $43K |
| 73562 | <1% | 1,577 | $42K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,612 | $41K |
| 73610 | <1% | 1,602 | $40K | |
| 82947 | <1% | 20,385 | $38K | |
| 84520 | <1% | 18,830 | $37K | |
| 73630 | <1% | 1,783 | $35K | |
| 93971 | <1% | 622 | $34K | |
| 84460 | <1% | 13,686 | $34K | |
| 84450 | <1% | 13,692 | $33K | |
| 84075 | <1% | 13,687 | $32K | |
| 81003 | <1% | 29,120 | $32K | |
| 73130 | <1% | 1,483 | $32K | |
| 82247 | <1% | 13,686 | $31K | |
| 82040 | <1% | 13,686 | $31K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,828 | $31K |
| 80305 | <1% | 5,437 | $31K | |
| 73110 | <1% | 907 | $27K | |
| 84155 | <1% | 13,689 | $23K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 109 | $22K |
| 73030 | <1% | 1,136 | $21K | |
| 96376 | <1% | 2,210 | $21K | |
| 83605 | <1% | 3,873 | $20K | |
| 74018 | <1% | 1,198 | $19K | |
| 84702 | <1% | 2,429 | $18K | |
| 85379 | <1% | 3,245 | $17K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 907 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,680 | $16K |
| 87420 | <1% | 2,288 | $15K | |
| 90715 | <1% | 626 | $15K | |
| 12001 | <1% | 446 | $14K | |
| 87040 | <1% | 2,258 | $13K | |
| 82805 | <1% | 1,096 | $13K | |
| 87400 | <1% | 1,514 | $11K | |
| 70486 | <1% | 66 | $10K | |
| 72131 | <1% | 107 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,149 | $10K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 883 | $10K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,749 | $8K |
| 0450 | Emergency room services | <1% | 195 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,295 | $6K |
| 12011 | <1% | 143 | $6K | |
| 72100 | <1% | 277 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,418 | $5K |
| 87210 | <1% | 2,280 | $5K | |
| 73140 | <1% | 181 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 42 | $4K |
| 82803 | <1% | 428 | $4K | |
| 73080 | <1% | 148 | $4K | |
| 87807 | <1% | 549 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,317 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,183 | $3K |
| 85610 | <1% | 1,750 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 73 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,527 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,142 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 397 | $2K |
| 10060 | <1% | 26 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,860 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 174 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $2K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 725 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,047 | $1K |
| 96368 | <1% | 146 | $866.40 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 26 | $831.89 |
| 86901 | <1% | 448 | $763.11 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 906 | $599.86 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 153 | $534.63 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,188 | $491.13 |
| 73090 | <1% | 24 | $459.55 | |
| 96367 | <1% | 49 | $453.73 | |
| 72040 | <1% | 15 | $363.12 | |
| 71101 | <1% | 12 | $314.10 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 227 | $266.12 |
| 73590 | <1% | 13 | $250.03 | |
| 82948 | <1% | 200 | $235.85 | |
| 73502 | <1% | 14 | $201.32 | |
| 99406 | <1% | 33 | $144.42 | |
| 86900 | <1% | 68 | $126.63 | |
| 0250 | <1% | 308 | $76.80 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 37 | $73.38 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 105 | $70.39 |
| 87070 | <1% | 13 | $64.68 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 15 | $50.35 |
| 82553 | <1% | 82 | $33.10 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 44 | $32.92 |
| J1815 | Injection, insulin, per 5 units | <1% | 19 | $8.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUCK, JOHN (PRESIDENT)
Parent organizationDE CRAIG RANCH, LLC
| Provider | Location | Paid |
|---|---|---|
| HCN Ep Horizon City, LLC | Horizon City, TX | $20.85M |
| De Craig Ranch, LLC | Las Vegas, NV | $7.84M |
| Iacc/Ehi NW, LLC | Oklahoma City, OK | $6.14M |
| Iacc/Ehi NW, LLC | Del City, OK | $6.01M |
| Iacc/Ehi NW, LLC | Oklahoma City, OK | $4.30M |
| De Craig Ranch, LLC | Las Vegas, NV | $3.05M |
| De Craig Ranch, LLC | Las Vegas, NV | $1.62M |
| Emp Idaho Nampa, LLC | Nampa, ID | $1.38M |
| Iacc/Ehi NW, LLC | Moore, OK | $757K |
| SCL Health Westminster, LLC | Northglenn, CO | $25K |
| SCL Health Westminster, LLC | Littleton, CO | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.